A breakthrough oral drug, daraxonrasib, significantly extended survival and reduced the risk of death compared to chemotherapy in a major Phase 3 trial for late‑stage pancreatic cancer.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045